UPDATE: What Amarin Would Need To Disclose To Ensure Non-Misleading Speech

"To ensure that this speech is non-misleading, Amarin would also disclose the following: •FDA has not approved to Vascepa reduce the risk of coronary heart disease; •The effect of Vascepa on the risk of cardiovascular mortality and morbidity has not been determined; •A cardiovascular outcomes study of Vascepa designed to evaluate the efficacy of Vascepa in reducing cardiovascular mortality and morbidity in a high-risk patient population on statin therapy is currently underway; •Vascepa may not be eligible for reimbursement under government healthcare programs, such as Medicare or Medicaid, for treatment of statin-treated patients with mixed dyslipidemia and high (≥ 200 mg/dL and < 500 mg/dL) triglyceride levels or to reduce the risk of coronary heart disease. We encourage you to check that for yourself; and •Any potential financial or affiliation biases between the firm and those who conducted the ANCHOR study."